Investor News

VIB spin-off MRM Health reports positive preclinical results in non-alcoholic fatty liver disease

MRM Health is a VIB spin-off founded in 2020 by Sam Possemiers in a joint venture with VIB. Using a 9-strain bacterial consortium, MRM Health’s laboratories led by Dr. Salvador Augustin and Dr. Maria Martell of the University Hospital of Vall d’Hebron were able to slow down disease progression in Non-Alcoholic Fatty Liver Disease (NAFLD). Preclinical results show that a live bacterial consortium of 9 rationally selected gut commensal strains were able to improve portal hypertension, insulin signaling, and NAFLD activity score. Additionally, the consortium helped prevent fibrosis development in two different in vivo disease models of Non-Alcoholic Steatohepatitis (NASH), improving endothelial functions and rebalancing the gut microbiome.

Lies Vanneste

Lies Vanneste

Investor Relations Manager, VIB

Share

Latest stories

Website preview
Scientists discover new gatekeeper cell in the brain
Ghent, 12 February 2026 – VIB and Ghent University researchers have identified and characterized a previously unknown cellular barrier in the brain, which sheds new light on how the brain is protected from the rest of the body. In a study published in Nature Neuroscience, the scientists also reveal a new pathway by which the immune system can impact the brain.
press.vib.be
Website preview
Researchers develop more reliable platform to test antibody medicines
Ghent, 30 January 2026 – An international research consortium has validated a new platform that could change how antibody medicines are tested and brought to patients. The work, published in Science Immunology, highlights problems during conventional antibody drug testing and introduces a next-generation mouse model that makes it possible to predict the effects of antibody drugs in humans more accurately.
press.vib.be
Website preview
Researchers uncover axonal protein synthesis defect in ALS
Leuven, January 12, 2026 – Researchers at VIB and KU Leuven have identified a molecular process that allows motor neurons to maintain protein production, a process that fails in amyotrophic lateral sclerosis (ALS). The study, published in Nature Neuroscience, reveals an early weakness in neurodegeneration and highlights a potential target for future therapies.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be